Different strategies to suppress the expression or activity of mutated IDH1 or to inhibit the production of 2-hydroxyglutarate with metabolites such as oxaloacetate have been evaluated in vitro and in clinical trials including a currently performed phase-I trial on gliomas [37]. The gene discussed is IDH1; the disease is central nervous system cancer.